4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde | 107430-91-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde
• 英文别名: 3-(1-adamantanyl)-4-methoxybenzaldehyde；3-(1-adamantyl)-4-methoxy benzaldehyde；3-(1-admantanyl)-4-methoxybenzaldehyde；3-(1-adamantyl)-4-methoxybenzaldehyde
• CAS: 107430-91-1
• 化学式: C₁₈H₂₂O₂
• 分子量: 270.371
• InChiKey: LEOWBFINLQCSFC-UHFFFAOYSA-N

物化性质

• 沸点：
  424.6±38.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde 在 盐酸羟胺 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 反应 6.0h， 以75%的产率得到4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde oxime
  参考文献：
  名称：

  Novel Terphenyls and 3,5-Diaryl Isoxazole Derivatives Endowed with Growth Supporting and Antiapoptotic Properties

  摘要：

  A new study on terphenyl and diaryl-isoxazole and isoxazoline derivatives, maintaining a common 3-adamantyl-4-hydroxyphenyl moiety, has been conducted to find compounds with growth supporting and antiapoptotic properties. Unexpectedly, diphenyisoxazole derivatives bearing a nitro group replacing the carboxylic function have been found with the highest cell protective activity within the series, in complete and in serum-free conditions. Inhibition of apoptosis induced by daunorubicin has also been observed for the most active compound.

  DOI：

  10.1021/jm800388m
• 作为产物：
  描述：

  2-(1-金刚烷基)-4-溴苯甲醚 在 盐酸 、 sodium chloride 、 碳酸氢钠 、 magnesium 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以80%的产率得到4-methoxy-3-tricyclo[3.3.1.1(0,0)]dec-1-yl benzaldehyde
  参考文献：
  名称：

  Polycyclic aromatic derivatives, process for preparing the same and

  摘要：

  具有以下结构式##STR1##的多环芳香化合物及其盐在治疗银屑病方面具有有用的治疗和美容作用。在该结构式中，X代表--CH.dbd.CH--，O或S，R.sub.1代表氢，具有3-15个碳原子的支链烷基，具有1-6个碳原子的烷氧基或1-金刚烷基，R.sub.2代表羟基，氢，具有1-15个碳原子的直链或支链烷基或具有1-6个碳原子的烷氧基，但要求R.sub.1和R.sub.2不能同时为氢，或者R.sub.1和R.sub.2连同萘环的相邻碳原子形成一个可选择由至少一个较低烷基基团取代的5或6链环，或者由一个氧原子中断，R.sub.3代表--CH.sub.2 OH或--COR.sub.4，或者当R.sub.1和R.sub.2连在一起形成一个5或6链环时，R.sub.3代表--CH.sub.3，R.sub.4代表--OR.sub.5或##STR2##，R.sub.5代表氢，具有1-20个碳原子的烷基，单羟基烷基，多羟基烷基，芳基或芳基烷基，可选择取代，或者糖的残基或基团##STR3##，p为1、2或3，r'和r"代表氢，较低烷基，单羟基烷基，多羟基烷基，可选择取代的芳基或氨基酸的残基或氨基糖的残基，或者连在一起形成一个杂环。

  公开号：

  US05124473A1

文献信息

• [EN] S1P RECEPTORS MODULATORS AND THEIR USE THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010043000A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及包括本发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如自身免疫反应。
• [EN] S1P RECEPTORS MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010042998A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  该发明涉及具有S1P受体调节活性的新化合物，最好具有对癌细胞和其他细胞类型具有凋亡活性和/或抗增殖活性。此外，该发明涉及包含该发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如癌症。该发明的另一个方面涉及使用包含该发明中至少一种化合物的药物制备药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如癌症。
• Bi-aromatic compounds and pharmaceutical and cosmetic compositions
  申请人：Centre International De Recherches Dermatologiques Galderma (CIRD

  公开号：US05869067A1

  公开（公告）日：1999-02-09

  The present invention relates to new aromatic compounds, to their preparation and to their use in human and veterinary medicine and in cosmetic compositions.

  本发明涉及新的芳香化合物，其制备方法以及它们在人类和兽医学以及化妆品组合物中的应用。
• S1P Receptors Modulators
  申请人：Grobelny Damian W.

  公开号：US20120034270A1

  公开（公告）日：2012-02-09

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  本发明涉及一种具有S1P受体调节活性的新化合物，优选具有凋亡活性和/或抗癌细胞和其他细胞类型增殖活性。此外，本发明涉及一种药物，包括本发明中至少一种化合物，用于治疗由于或与不适当的S1P受体调节活性或表达相关的疾病和/或状况，例如癌症。本发明的另一方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由于或与不适当的S1P受体调节活性或表达相关的疾病和/或状况，例如癌症。
• S1P Receptors Modulators and Their Use Thereof
  申请人：Gill Gurmit S.

  公开号：US20110318388A1

  公开（公告）日：2011-12-29

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  本发明涉及具有S1P受体调节活性的新化合物。此外，本发明涉及包括本发明中至少一种化合物的药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。